An emerging oncology tool known as broad genomic profiling or BGP is increasingly being used to help identify targeted ...

Christine Lote, 41, was an avid runner before her mystery injury - which left her with a swollen right foot. She was diagnosed with stage four cancer after giving birth to her daughter, Sophie ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Nuvation Bio's taletrectinib shows strong efficacy in ROS1-positive NSCLC, with a 90.1% response rate. Click here to find out ...

Raymond Osarogiagbon, MD, shares practical strategies for clinicians and health systems to boost lung cancer screening rates among eligible patients.

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Raymond Osarogiagbon, MD, highlights the potential benefits of increasing screening rates for patients diagnosed with lung cancer and the broader US health care system.

Although lung cancer screening ... A Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions Mar. 17, 2025 — In the continuing evolution of personalized medicine, a new study has ...

Expanding accessibility to early detection would improve treatment outcomes, reduce mortality, and minimized the emotional ...

The 'cell of origin' of the second most common lung cancer and the way that it becomes dominant in the lung have been discovered, in a new study in mice and humans from researchers at UCL, the ...